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Abstract
Transposon-mediated transformation was used to produce Anopheles stephensi that express single-chain antibodies (scFvs)
designed to target the human malaria parasite, Plasmodium falciparum. The scFvs, m1C3, m4B7, and m2A10, are derived
from mouse monoclonal antibodies that inhibit either ookinete invasion of the midgut or sporozoite invasion of salivary
glands. The scFvs that target the parasite surface, m4B7 and m2A10, were fused to an Anopheles gambiae antimicrobial
peptide, Cecropin A. Previously-characterized Anopheles cis-acting DNA regulatory elements were included in the
transgenes to coordinate scFv production with parasite development. Gene amplification and immunoblot analyses showed
promoter-specific increases in transgene expression in blood-fed females. Transgenic mosquito lines expressing each of the
scFv genes had significantly lower infection levels than controls when challenged with P. falciparum.
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Introduction
Plasmodium falciparum, a causative agent of human malaria, is a
vector-borne parasite that is responsible for more than 500 million
clinical disease cases each year [1]. The selection of insecticide-
resistant mosquitoes and drug-resistant parasites necessitates an
ongoing search for new disease-control methods. A proposed
strategy for interrupting transmission is to replace wild, malaria-
susceptible mosquito populations with transgenic, Plasmodium-
resistant mosquitoes [2–4]. Key components of this approach are
effector molecules that inhibit parasite development when
expressed from a transgene. The mechanisms by which effector
molecules function can vary greatly, as the development of the
malaria parasites within mosquitoes involves several transitions of
environment, physiology and morphology [5].
When mosquitoes feed on infected humans, they ingest parasites
in the form of gametocytes. These produce gametes that fuse to
form diploid zygotes that develop into the motile ookinetes. The
ookinetes invade and traverse the mosquito midgut epithelium and
then rest beneath the basal lamina of the midgut, forming oocysts.
Thousands of sporozoites develop within the oocysts before
budding out into the circulatory fluid, the hemolymph, and
invading the salivary glands. Several effector molecules have been
tested for their ability to target the parasite during either early
sporogony in the midgut, or late sporogony in the hemolymph or
salivary glands [5–8]. An effector mechanism based on the
mosquito signaling protein Akt is the only one to date shown to
inhibit completely P. falciparum development in a transgenic
Anopheles mosquito [7].
One effector molecule strategy exploits the finding that
monoclonal antibodies (mAbs) that recognize surface-bound or
secreted parasite molecules can inhibit pathogen development [9–
14]. Two mAbs, 4B7 and 1C3, target parasites early in their
development within mosquitoes. 4B7 binds P. falciparum surface
protein Pfs25, a molecule expressed on the surface of ookinetes,
and inhibits parasite development completely when fed to Anopheles
mosquitoes in a gametocytemic bloodmeal [9]. In contrast, 1C3
binds a parasite-secreted enzyme, P. falciparum chitinase 1, and
inhibits oocyst formation of P. falciparum when incorporated into
infectious bloodmeals [10]. A third mAb, 2A10, binds P. falciparum
circumsporozoite protein (CSP), and when pre-incubated with
sporozoites, greatly decreases their ability to infect cultured
hepatocytes [11,12].
Although the size and complexity of mAbs exclude them from
consideration as potential effector molecules, single-chain anti-
bodies (scFvs), which retain the binding specificity of a mAb, are
much smaller and can be produced from a single transcription unit
[15]. An scFv targeting the P. gallinaceum CSP inhibited sporozoite
invasion of salivary glands in Aedes aegypti in both transient assays
and transgenic mosquitoes [13,16]. Anopheles stephensi fed Escherichia
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have significantly-reduced oocyst densities when fed on parasite-
infected mice [14]. Furthermore, an scFv derived from the 1C3
mAb reduced significantly P. falciparum parasite transmission to
mosquitoes [17]. The experiments described in the work presented
here test the scFv-based strategy on human malaria parasites in
transgenic mosquitoes and support the further development and
evaluation of these molecules as disease-control tools.
scFvs based on the 1C3, 4B7 and 2A10 mAbs were expressed in
transgenic An. stephensi and their efficacy tested in parasite
challenge assays with P. falciparum. Anopheles stephensi was chosen
because it is a significant vector of urban malaria transmission in
the Indian subcontinent and is an efficient model for transgenic
research. To distinguish the novel scFvs developed in this study,
we refer to them as ‘‘modified’’ 1C3, 4B7 or 2A10 (m1C3, m4B7,
m2A10). For the m4B7 and m2A10 transgenes, the An. gambiae
Cecropin A gene (AgCecA) was joined to the scFv gene to form a
single open reading frame (ORF). Cecropin A is an antimicrobial
peptide that has microbiocidal activity against both gram-negative
and gram-positive bacteria, as well as multiple Plasmodium species
[18,19]. This broad activity is due to its ability to form large pores
in cell membranes [20]. With the addition of cecropin A, the
m4B7 and m2A10 scFvs possess both parasite-binding and
antimicrobial activity. The cecropin A peptide was not joined to
m1C3 as the target of this scFv is a secreted molecule [17].
Anopheles gambiae carboxypeptidase A (AgCPA [21,22]) gene regula-
tory sequences were included in m4B7 and m1C3 transgenes to
coordinate their expression with the development of ookinetes.
Anopheles stephensi vitellogenin 1 (AsVg1 [23]) regulatory elements were
joined to the m2A10 scFv to direct transgene expression in the
female fat body. Thus, m2A10 secreted from the fat body into the
hemolymph could encounter sporozoites migrating to the salivary
gland. When challenged in multiple experiments with P. falciparum
infectious gametocyte cultures, scFv-expressing transgenic lines
displayed statistically-significant, reduced mean intensities of
infection and in most trials lower parasite prevalence when
compared to control mosquitoes.
Results
Transgene assembly, transgenesis, and gene copy-
number analyses
The scFv genes were synthesized commercially to incorporate
either the AgCPA signal sequence or the entire AgCecA ORF
(Figure 1). Codons corresponding to the amino acids serine,
proline, alanine, threonine, and arginine displayed the greatest
frequency bias differences between Mus musculus and An. gambiae
(Table S1) [24], and these were replaced in the mouse-derived
scFv sequences by those favored by the mosquito. DNA sequence
encoding a short polypeptide linker (five amino acids) was used to
join the heavy- and light-chain variable fragments of m4B7 and
m2A10 scFvs and a longer linker (encoding 15 amino acids) joined
the two corresponding moieties of m1C3. Long linkers permit
intramolecular pairing of variable fragments, while short linkers
favor the intermolecular joining of scFv molecules to form
multimers containing multiple antigen recognition sites [25].
The m1C3 and m4B7 scFv genes were joined to AgCPA regulatory
elements and inserted into a pBac [3xP3-EGFP] plasmid to
construct the transformation vectors (Figure 2). Similarly, the
m2A10 scFv gene was joined to AsVg1 regulatory elements and
inserted into a pBac [3xP3-dsRed] plasmid.
The three transformation plasmids pBac [3xP3-EGFP]-m1C3,
pBac [3xP3-EGFP]-m4B7 and pBac [3xP3-dsRed]-m2A10 were
injected into 980, 615 and 765 embryos, respectively. Three
transgenic m1C3 mosquito lines (21.1, 39.1 and P4.1) were
established from EGFP-positive families derived from 78 surviving
adults. Two transgenic m4B7 mosquito lines (25.1 and P6.1) were
established from 89 adults, and seven transgenic m2A10 mosquito
lines (18.1, 20, 34.1, 39.1, 44.1, P5.1 and P7.1) were established
from 105 adults.
Southern blot analyses were used to verify transgene insertions
and to determine the number of integrated constructs in each line
(Figure 2). Hybridization of an m1C3 probe to genomic DNA
digested with both SphI and XhoI restriction endonucleases
produced a diagnostic fragment of ,1.2 kilobase pairs (kb) in
transgenic samples, confirming m1C3 integration. Genomic DNA
digested with SpeI and hybridized to an EGFP probe produced
multiple fragments in each transgenic sample, indicating that there
were at least three, nine, and ten copies in lines 21.1, 39.1, and
P4.1, respectively. Genomic DNA digested with ApaI, AscI, and
FseI, and hybridized to a probe complementary to the m4B7 gene
and the AgCPA 39UTR produced two diagnostic fragments of 940
and 810 base pairs (bp), verifying transgene insertion. A second
blot, comprising XhoI-digested genomic DNA recovered from
transgenic mosquitoes and hybridized with a 3XP3 EGFP probe,
revealed several fragments in each sample, indicating that at least
four copies of the m4B7 transgene were present in each line.
Lastly, genomic DNA digested with both XbaI and BamHI and
hybridized to an m2A10 probe produced an ,1 kb diagnostic
fragment in each transgenic sample. The same probe hybridized to
HindIII-digested genomic DNA bound multiple DNA fragments in
each m2A10 sample, indicating the presence of six, three, three,
four, six, seven and three copies in transgenic lines 18.1, 20, 34.1,
39.1, 44.1, P5.1, P7.1, respectively. Transgenic lines were
maintained by intercrossing at each generation. However,
selection pressures on individual transgene insertions, small
founding colony sizes and independent assortment likely result in
loss over time of some of the insertions.
Characterization of transgene expression
Reverse-transcriptase-PCR (RT-PCR) and Real-time quantita-
tive RT-PCR (RT-qPCR) were used to evaluate the presence and
Author Summary
Malaria eradication will require vector-control strategies
that are both self-sustaining and not affected by migration
of infected humans and mosquitoes. Replacement of wild
malaria-susceptible mosquito populations with transgenic
strains refractory to parasite development could interrupt
the cycle of disease transmission and support eradication
efforts. Production of P. falciparum-resistant mosquitoes is
a necessary first step towards investigating the population
replacement strategy. Here we show that An. stephensi
engineered to produce P. falciparum-targeting effector
molecules are resistant to this important human malaria
parasite. Two of the three effector molecules represent a
novel combination of components derived from the
immune systems of mosquitoes and mice. An important
feature of these molecules is that they are unlikely to
significantly harm the mosquito, as the mosquito compo-
nent is an Anopheles antimicrobial peptide with activity
against Plasmodium, while the other component is based
on a murine antibody selected for its ability to bind
specifically to a parasite protein. Transgenes with this
design coupled with a gene-drive system could be used
alongside vaccines and drugs to provide sustainable local
elimination of malaria as part of a long-term strategy for
eradication.
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products in non-blood-fed and blood-fed mosquitoes in all of the
established transgenic lines. No significant correlation was seen
between transgene copy number and amount of transcription
product detected (data not shown). Therefore, the lines m1C3
P4.1, m4B7 25.1 and m2A10 44.1, each of which displayed the
highest levels of transcript accumulation in their respective group,
were selected for use in all further analyses. Southern blot analyses
of the generations of m1C3 P4.1, m4B7 25.1 and m2A10 44.1
used in the challenge assays indicated the presence of eight, four,
and four copies of the respective transgenes.
Transgene-specific transcript accumulation profiles detected by
RT-PCR were similar in mRNA samples prepared from the
dissected midguts of m1C3 P4.1 and m4B7 25.1 females (Figure 3).
Both lines showed constitutive accumulation in midguts from non-
blood fed mosquitoes. In addition, each line showed accumulation
of their respective mRNAs at 4 hours post-bloodmeal (hPBM),
and signals were evident at 12 and 24 hPBM. m4B7 transcript also
could be detected at low levels at 48 hPBM. No amplification
products were produced from mRNA prepared from female
carcasses or males of each line. As expected, control reactions
using mRNA from midguts dissected at 4 hPBM from wild-type,
non-transgenic females were negative. RT-qPCR analysis at
multiple post-bloodmeal time points was used as an independent
measure of m1C3 P4.1 expression. The highest measured level of
m1C3 mRNA, 10,000-fold above the control level, was observed
in the 16 hPBM midgut sample (paired T-test, one tailed p-
value=0.005), but similar elevated levels also were seen at 24 and
48 hPBM. At this time, we cannot account for the difference in the
RT-PCR and RT-qPCR results at 48 hPBM, although this could
result from individual females that responded differentially to the
feeding regimen. This difference is not expected to have affected
Figure 1. A model of the modified scFv transgenes. A mature mouse immunoglobulin molecule consists of two heavy- and light-chain
polypeptides each linked through disulfide (ss) bonds (top image). The single-chain antibodies are composed of the variable regions (Fv) of the heavy
(VH) and light (VL) chains (gray and open boxes, respectively) of a mouse monoclonal antibody. The m4B7 and m2A10 scFv transgenes encode a short
polypeptide linker of 5 amino acids (5aa) between VH and VL. These transgenes include sequence for a long polypeptide linker of 15 amino acids
(15aa) joining the VH to the An. gambiae Cecropin A peptide (CecA), including its signal sequence. The VH region present in the m1C3 transgene is
joined to the An. gambiae Carboxypeptidase A gene signal sequence, and joined by a long polypeptide linker to the VL region. Select codons in the
variable region genes were codon-optimized to facilitate efficient translation. Anopheles promoter sequences (P) were joined to the scFvs to direct
tissue-specific transgene expression.
doi:10.1371/journal.ppat.1002017.g001
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parasites within the first 24 hPBM.
Immunoblot analyses of m1C3 and m4B7 transgenic mosquitoes
were unproductive despite repeated attempts. Although high levels
of proteinase inhibitors were used during sample preparation, it is
possible that the transgene products were degraded quickly in the
strong digestive milieu of the post-feeding midgut lumen.
Transgene transcripts detected in whole transgenic m2A10 44.1
females showed sex- and stage-specificity (Figure 3). No signals were
seen in samples derived from mRNA prepared from males and non-
blood fed transgenic or control wild-type, non-transgenic females.
Specifictranscriptaccumulationwas evidentinm2A1044.1females
at 12 and 24 hPBM in an expression pattern similar to that of
endogenous AsVg1, but was not as abundant at 48 hPBM.
Figure 2. Southern blot analyses of m1C3, m4B7, and m2A10 transgenic lines. (A) Schematic representations of the single-chain antibody
(scFv) transformation constructs. The scFv heavy (VH) and light (VL) variable region genes in the m1C3 construct are joined by sequence encoding a
long polypeptide linker (multiple grey boxes). The sequence encoding the VH is joined to the An. gambiae carboxypeptidase A signal sequence (AgCp
sig). In the m4B7 and m2A10 constructs, the An. gambiae Cecropin A gene (CecA), including signal sequences (CecA sig), is joined by sequence
encoding a long polypeptide linker to the scFv VH and VL genes. The VH and VL genes are joined by a short polypeptide linker (single grey box). All
three scFvs are joined to an epitope tag (E tag). The CecA-m2A10 effector gene is flanked by An. stephensi vitellogenin 1 regulatory sequences (AsVg 59
UTR, 39UTR), while the m1C3 and CecA-m4B7 genes are flanked by AgCP A regulatory sequences (AgCp 59 UTR, 39UTR). A transformation marker (EGFP
or DsRed) joined to the Pax3 (3xP3) promoter and the SV40 polyadenylation sequence also is contained between the piggyBac transposase arms
(pBacLH, RH). Select restriction endonuclease sites present in the transgene are indicated in the diagram. Probes used to identify the integrated
transgenes are indicated by horizontal bars above each schematic representation. (B) Genomic DNA from m1C3 and wild-type control females was
digested and hybridized to either an EGFP probe (left) or an m1C3 probe (right). (C) Genomic DNA from m4B7 and wild-type control females was
digested and hybridized to either an EGFP probe (left) or an m4B7/AgCPA 39UTR probe (right). (D) Genomic DNA from m2A10 and wild-type control
females was digested and hybridized to an m2A10 probe. The restriction endonucleases used in each experiment are listed above the blot, and the
identity of each transgenic line is listed above each lane. The locations of molecular weight markers are indicated in kilobase pairs (kb).
doi:10.1371/journal.ppat.1002017.g002
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during the first 24 hours post-bloodmeal, expression of m2A10
must be sustained over several days, as oocysts can mature
asynchronously [26]. Denaturing immunoblot analyses were
performed on m2A10 44.1 females sampled over the course of
four bloodmeals to evaluate whether protein expression could be
induced repeatedly (Figure 4; Figure S1). Anti-E tag antibody
specifically detected a polypeptide with an approximate Mr of 32
kiloDaltons (kDa), consistent with the predicted size of m2A10
protein, in transgenic blood-fed females at 24, 48, 72 and 96
hPBM. The continuous presence of m2A10 was detected in
females that were given bloodmeals once every five days.
Expression of m2A10 also was observed at 12 hPBM in additional
immunoblot analyses (data not shown). Immunoblots of hemo-
lymph samples indicated that m2A10 protein was present in the
hemolymph of blood-fed transgenic females (Figure 4). Immuno-
blot analyses of hemolymph samples analyzed in non-denaturing
conditions detected m2A10 protein in several multimeric confor-
mations with estimated Mrs of 125, 223, 284, and 485 kDa.
Plasmodium falciparum challenge of transgenic and
control mosquitoes
Parasite challenge experiments were performed to test the
efficacy of the anti-pathogen effector molecules. Transgenic and
control mosquitoes ingested blood containing P. falciparum
gametocytes through a membrane-feeding apparatus. Control
mosquitoes for most experiments were non-transgenic (wild-type)
mosquitoes. In addition, the oocyst prevalence and mean
intensities of infection of a group of m2A10 44.1 females were
examined for each challenge experiment to determine whether
transgenesis alone had an impact on parasite development.
The effect of transgene expression on parasite development for
both the m4B7 25.1 and m1C3 P4.1 transgenic lines was
measured by comparing the number of oocysts in transgenic and
control mosquito midguts at nine days after the infectious
bloodmeal (Table 1; Figure 5). The mean intensities of oocyst
infection were reduced by 37–81% in three challenge experiments
(1, 2 and 3, Table 1) of m4B7 25.1. However, the mean intensities
of infection were reduced by only 29–36% in two experiments (4
and 5, Table 1) in which control mosquitoes had greater than 17
oocysts per midgut. Mean intensities of oocyst infection were
reduced by 47–73% in mosquitoes expressing m1C3 when
compared to controls. Furthermore, with the exception of the
high infection-level experiments (4 and 5, Table 1), both m1C3
P4.1 and m4B7 25.1 transgenic mosquitoes had lower prevalence
of infections than controls.
Parasite challenge assays of m2A10 44.1 involved dissecting 7–
11 mosquitoes of each group 10 days after the infectious
bloodmeal to count midgut oocysts and to confirm that both
transgenic and control mosquitoes were infected successfully
(Table 2). No statistically significant difference in the number of
oocysts between transgenic m2A10 44.1 and control mosquitoes
was observed (Mann-Whitney U test, one-tailed P value,
0.24,p,0.48). The remaining mosquitoes (n=8–50) in each
group were examined 17–19 days after infection for the presence
of sporozoites in the salivary glands (Table 2; Figure 5). All
mosquitoes were provided an uninfected bloodmeal every five days
to maintain expression of m2A10. Engorged and un-engorged
females were not separated after the uninfected bloodmeals in
experiments 1, 2, 3 and 4, and a 52–84% reduction in mean
intensity of sporozoite infection was observed in transgenic
mosquitoes when compared to the controls. To obtain a more
precise measurement of the effect of m2A10 expression upon P.
falciparum development, an additional three experiments (5, 6 and
7) were performed in which un-engorged females were discarded
after each uninfected bloodmeal. A 96–97% reduction of mean
intensity of infection was observed in m2A10 44.1 mosquitoes that
fed every five days. Furthermore, m2A10 44.1 mosquitoes in
experiment 7 had a 14% prevalence of infection compared to 78%
observed in the corresponding control.
Discussion
Previous evaluations of mosquitoes engineered genetically to
express anti-Plasmodium effector genes featured analyses of
transgene copy numbers, transgene transcription levels, detection
of transgene effector proteins, binding of effector molecules to the
target parasite stage and a phenotype of reduced parasite mean
intensities of infection and prevalence [7,8,16,22,27–29]. Remark-
ably, no single study includes all of these data and the emphasis
has been on the impact of transgene presence on parasite
numbers. Expression of the two midgut-directed scFvs, m1C3
and m4B7, was detected by RT-PCR, but not by immunoblots.
The rapid degradation of these scFvs in the midgut environment
may have inhibited immunoblot detection. However, the obser-
vation that m4B7 25.1 and m1C3 P4.1 transgenic mosquitoes
have reduced parasite loads supports the conclusion that these
scFvs are expressed in the midgut. Both transgene transcription
and translation products were detected in m2A10 44.1 mosquitoes.
The finding that the immunoblot analyses of non-denatured
m2A10 44.1 samples detected the presence of scFv multimers is
consistent with the expectation that the short polypeptide linker
joining the VH and VL regions promotes intermolecular scFv
interactions. The size of these multimers was similar to the
predicted sizes of m2A10 multimers comprising four, seven, nine,
and fifteen scFv molecules. Such scFv multimers are reported to
have high affinity to target epitopes [25].
Both m1C3 and m4B7 expressed in transgenic lines P4.1 and
25.1, respectively, inhibited parasite development during early
Figure 3. Expression of m1C3 P4.1, m4B7 25.1, and m2A10 44.1 transgenes. Representative results of gene amplification experiments show
tissue- (A, B, C), sex- (A, B, C) and stage-specific (C) accumulation of transgene transcription products. (A) RT-PCR was used to detect m4B7 and
endogenous An. stephensi carboxypeptidase A (AsCPA) transcript in RNA isolated from either whole m4B7 25.1 transgenic males (M) or dissected wild-
type (WT) control, non-blood-fed m4B7 25.1 transgenic females (NBF) and m4B7 25.1 transgenic females at multiple post-bloodmeal time points
(indicated above each lane). For female samples, RNA was extracted from either gut or carcass homogenates. (B) RT-PCR was used to detect m1C3
and endogenous An. stephensi carboxypeptidase A (AsCPA) transcript as described in (A). The An. stephensi S26 ribosomal protein transcript (rpS26)
was amplified as a loading control in all RT-PCR experiments. (C) Accumulation of m2A10 44.1 and endogenous An. stephensi vitellogenin (AsVg1)
transcript in transgenic males, non-blood-fed females, and females at multiple post-bloodmeal time points was assayed by RT-PCR. RNA was isolated
from adult whole-body homogenates of wild-type control and m2A10 44.1 transgenic mosquitoes. RNA from wild-type control females was included
as both a positive control for AsVg1 expression and as a negative control for m2A10 44.1 amplification. Parallel reactions in which the reverse
transcription reaction step were omitted demonstrated that the observed amplification products originated exclusively from RNA (data not shown).
(D) Developmental expression of m1C3 mRNA. m1C3 mRNA abundance in the midguts of females is described as transcript numbers in log-scale.
Each data point represents the average of three independent biological replicates. An asterisk indicates a significantly larger number of transcripts
when compared to NBF (paired T-test, one tailed p-value, 16 h p=0.0050, 24 h p=0.0067, 48 h p=0.0018).
doi:10.1371/journal.ppat.1002017.g003
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oocyst infection in eight of ten challenge experiments. The results
of two of the m4B7 25.1 challenge experiments are consistent with
the interpretation that there is a threshold level of initial parasite
density above which this scFv, at the levels expressed in these
transgenic lines, cannot efficiently inhibit ookinete development.
The finding that m2A10 44.1 and wild-type control mosquitoes
did not differ in midgut infection supports the conclusion that
transgene integration alone does not necessarily impair parasite
development.
When expression of m2A10 in line 44.1 was induced repeatedly
by blood feeding, a highly significant decrease in sporozoite load
was observed in transgenic mosquito salivary glands. For this
transgenic line, the greatest reduction in prevalence was found in
an experiment in which the mean intensity of oocyst infection was
low. It is likely that these scFvs would effectively impair P.
falciparum transmission in field conditions, as infected wild-caught
An. gambiae carry few oocysts. Studies of An. gambiae by Billingsley
et al. [30] and Taylor [31] found mean numbers of oocysts per
infected mosquito of 1.55 and 3.38, respectively.
Incorporation of multiple transgenes is typical for piggyBac-
mediated insertions into An. stephensi [22,23,32]. Although it is
reasonable to expect that higher transgene copy numbers should
yield higher expression levels, no statistically-significant correla-
tions have been reported. We hypothesize that many of the
multiple copies have little or no expression as a result of position
effects, and that the majority of transgene expression comes from
single or small numbers of the transgenes. To mitigate copy-
number issues, we have used piggy-Bac-mediated transposition to
integrate target sites for QC31 site-specific recombination into
multiple locations in the An. stephensi genome and are now testing
individual lines for permissiveness for optimum transgene
expression [33]. These lines have the added benefit of having
been evaluated for the impact on fitness of the introduced
exogenous DNA at the specific insertion site, and therefore the
effects of anti-pathogen transgene product expression can be
Figure 4. Bloodmeal-induced expression of m2A10 scFv. (A) Immunoblot analyses of transgenic m2A10 44.1 An. stephensi. An anti-E tag
antibody was used to detect m2A10 protein in whole body homogenates of transgenic females. Purified m2A10 scFv protein, which contained an E
tag but did not contain Cecropin A, was used as a positive control (+). Female mosquitoes were given bloodmeals (bm) once every five days, and
examined at 24, 48, 72, and 96 hours after each meal. (B) An immunoblot of both whole females (W) and a hemolymph preparation of females (H)
from transgenic m2A10 44.1 and wild-type control mosquitoes (WT) 48 hours post-bloodmeal. Anti-E tag antibody was used for detection of m2A10.
(C) An immunoblot of m2A10 and wild-type control female hemolymph samples, prepared in non-denaturing conditions (left panel) and probed with
anti-E tag antibody. Non-bloodfed (NBF) and 24 hours post-bloodmeal (24hPBM) females were compared. NativeMark protein standard (Invitrogen)
was used for molecular weight estimation. Control images of the Coomassie-stained gels are provided in Figure S1.
doi:10.1371/journal.ppat.1002017.g004
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phenotype of dual transgenes, for example, those combining m4B7
and 2A10 or m1C3 and m2A10, on parasite mean intensities of
infection and prevalence. Additional studies facilitated by this
approach could include testing alternate gene regulatory sequenc-
es, such as those of the salivary gland-specific anopheline
antiplatelet protein or the An. gambiae adult peritrophic matrix
protein 1, to measure the effect of different transgene expression
patterns upon parasite development [34,35].
Although the scFvs in lines m1C3 P4.1, m4B725.1, and m2A10
44.1 inhibited parasite development significantly, no transgenic
line displayed zero prevalence of infection. It has been
demonstrated in an avian malaria model system comprising the
vertebrate host, Gallus gallus, the mosquito host, Aedes aegypti, and
the parasite, P. gallinaceum, that mosquitoes containing as few as 20
sporozoites in their salivary glands infected chickens during a
blood meal [16]. This finding supports the conclusion that a target
of zero prevalence is necessary for a transgenic mosquito to be
incapable of disease transmission in this system. These results are
in contrast to reports of experiments with transgenic mosquitoes
and a rodent malaria parasite, P. berghei, in which the effector
molecules SM1, PLA2 and CEL-III show a significant inhibition
of parasite development (81.6%, 87% and 84.8%, respectively)
[22,27,28]. Reductions of mean intensities of P. berghei sporozoite
infection in salivary glands below ,400 were sufficient to block
transmission. In contrast, experimental infections of humans with
P. vivax showed that 10 sporozoites were sufficient to cause malaria
[36]. We have opted to take the conservative approach and are
attempting to achieve zero prevalence of human parasites in
mosquito salivary glands [16].
Two anti-Plasmodium effector molecule strategies have yielded
transgenic mosquitoes with zero prevalence: expression of the
signaling molecule Akt, and expression of a combination of
Cecropin A and Defensin A [7,29]. The latter study was
conducted with the P. gallinaceum/Ae. aegypti/G. gallus model
system. The study of Akt demonstrated the feasibility of producing
an Anopheles mosquito that is completely resistant to P. falciparum,
however this effector molecule may not be an optimal component
of a population replacement strategy as these mosquitoes have a
significantly reduced lifespan [7]. A synthetic peptide designed to
interact with P. yoelii reduced midgut infections of this parasite by
67–87% in An. gambiae but was considerably less efficacious against
P. falciparum [8]. Quantitative comparisons of the efficacy of
alternative effector molecules are hindered currently by differences
in expression that result from variations in transgene location and
copy number. Site-specific recombination approaches will allow
such evaluations in well-characterized ‘docking-site’ mosquito
strains [8,33].
The finding that m2A10 44.1 mosquitoes display up to 97%
decreases in the mean intensity of P. falciparum infection, as well as
decreased prevalence of infection, supports the argument that this
scFv may be an effective component of a malaria resistance
transgene. The m1C3 and m4B7 scFv genes conferred significant
reductions in mean intensities of infection, and if expressed in
higher quantities, also may be used in the design of a transgenic,
parasite-resistant mosquito. Furthermore, expressing the scFv
transgenes in additional malaria vectors, in particular, An. gambiae,
and challenging these with a variety of P. falciparum isolates would
help evaluate whether these effector molecules could be used in
multiple transmission areas.
Table 1. Oocyst prevalence and mean intensity of infection in P. falciparum-infected mosquitoes.
Exp. Strain Oocyst prevalence
a (n) Mean intensity of oocyst infection
a +/2 SD (n) P
b
1 Control 84%(45) 15.3+/212.3 (38) ,0.0001
m4B7 48% (50) 2.9+/22.4 (24)
2 Control 70% (67) 4.6+/24.4 (47) ,0.0001
m4B7 41% (93) 2.9+/22.9 (38)
3 Control 77% (64) 6.3+/24.5 (49) ,0.0001
m4B7 40% (92) 2.4+/21.9 (37)
4 Control 88% (48) 19.8+/221.4 (42) 0.3736
m4B7 88% (43) 14.1+/210.5 (38)
5 Control 83% (46) 17.4+/217.8 (38) 0.2883
m4B7 88% (41) 11.2+/29.5 (36)
6 Control 83% (23) 22.5+/213.5 (19) 0.0068
m1C3 64% (22) 12.0+/211.6 (14)
7 Control 86% (22) 38.8+/236.8 (19) 0.0007
m1C3 46% (24) 14.3+/218.1 (11)
8 Control 48% (23) 7.1+/25.8 (11) 0.0004
m1C3 9% (33) 3.0+/22.0 (3)
9 Control 67% (12) 10.5+/24.4 (8) 0.0043
m1C3 39% (23) 3.9+/23.6 (9)
10 Control 46% (24) 3.7+/22.1 (11) 0.0065
m1C3 15% (20) 1.0+/20.0 (3)
aPrevalence reflects the percent of mosquitoes infected; mean intensity of infection reflects the mean number of parasites found in infected mosquitoes.
bA Mann-Whitney U test was used to evaluate statistical significance of oocyst mean intensity infection data. A one-tailed P value is listed for each experiment.
doi:10.1371/journal.ppat.1002017.t001
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that completely inhibit P. falciparum development will support the
engineering of mosquitoes that express multiple effector molecules.
Such mosquitoes may have a reduced likelihood of selecting for
resistant parasites. Along with vaccines, drugs, and insecticide-
treated nets, parasite-resistant transgenic mosquitoes would be a
useful component in a malaria-control strategy, especially in
regions where existing interventions have been unable to eliminate
disease transmission.
Materials and Methods
Mosquito rearing and maintenance
A colony of Anopheles stephensi (gift of M. Jacobs-Lorena, Johns
Hopkins University) bred in our insectary for .5 years was used in
the experiments. The mosquitoes were maintained in conditions
that maximize larval nutrition, and adult size and fitness [37].
These conditions include maintenance of cultures at 27uC with
77% humidity and 12 hr day/night, 30 min dusk/dawn lighting
cycle. Larvae were fed a diet of powdered fish food (Tetramin)
mixed with yeast. Adults were provided water and raisins ad
libitum. Anesthetized chickens, mice, or rabbits were used for blood
feeding. Transgenic and wild-type control mosquitoes used in
parasite challenge experiments were reared in parallel using
standardized insectary procedures.
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Intuitional Animal Care and Use
Committee of the University of California, Irvine (NIH Animal
Welfare Assurance number: A3416.01 (approved February 20,
2008), Protocol Number: 1998- 1411 (approved May 21, 2010).
The vertebrates used as bloodmeal donors for mosquitoes were
anesthetized on a regimen that avoids the build-up of drug
tolerance, and all efforts were made to minimize suffering.
scFv sequence modifications
The sequences of the 4B7 and 2A10 variable heavy- and light-
chain regions (VH and VL, respectively) were derived from cDNA
synthesized from 2A10 and 4B7 hybridoma cell lines (obtained
from E. Nardin [New York University], and the Malaria Research
and Reference Reagent Resource Center, respectively). 2A10
cDNA was synthesized from total RNA isolated from the
hybridoma cell line using primers designed from the known VH
and VL sequence [38]. VH and VL cDNA from the 4B7
hybridoma cell line was amplified from its total RNA using the
heavy and light primer mixes respectively, provided in the Mouse
ScFv Module/Recombinant Phage Antibody System (Amersham
Biosciences). The modified scFv genes, including either AgCPA
Figure 5. P. falciparum oocyst or sporozoite burden in transgenic and wild-type control mosquitoes. Box plots display the observed
distribution of oocyst per midgut or sporozoite per salivary gland pair values for wild-type control mosquitoes and m1C3 P4.1, m4B7 25.1, or m2A10
44.1 transgenic mosquitoes. The boxes in each panel represent from bottom to top the 25
th to 75
th percentiles, while the vertical lines and small
horizontal bars delimit the minimum and maximum values. Horizontal bars within the boxes indicate the median value of each group. (A) Plots of
data from all challenge experiments with m4B7 25.1 and m1C3 P4.1 mosquitoes. (B) The plot represents data from m2A10 44.1 experiments 1–4 and
5–7 separately, as indicated.
doi:10.1371/journal.ppat.1002017.g005
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commercially (Epoch Biolabs) to allow for incorporation of novel
features. The variable regions of 4B7, 2A10, and 1C3 [17] were
optimized by replacing the codons corresponding to the amino
acids serine, proline, alanine, threonine, and arginine in the
mouse-derived sequences with those favored in An. gambiae (Table
S1) [24]. For the m4B7 and m2A10 scFvs, the variable regions
were joined by sequence encoding a short polypeptide linker, G4S.
The VH region of the m2A10 and m4B7 scFv sequences were
joined to the AgCecA protein-coding sequence by a long
polypeptide linker, (G4S)3 [39]. The variable regions of m1C3
were joined by the same long polypeptide linker. The m2A10 VL
was joined to sequence encoding a complete E tag, while the VL of
m4B7 and m1C3 were joined to sequence encoding a partial E
tag. For m4B7 and m1C3, the remaining E tag coding sequence
was joined to the partial E tag at a later cloning step.
Transformation plasmid assembly
The pBacDsRed-AsVg59-m2A109-AsVg39 plasmid was pro-
duced in two cloning steps. First, m2A10 sequence from the
commercially-synthesized pBSKm2A10 plasmid replaced the CFP
gene of pSLfa-AsVg59-CFP-AsVg39 [23] using XbaI and BamHI
sites. Second, the AsVg59-m2A10-AsVg39 sequence was joined to
pBacDsRed [37] using AscI sites. A pSLfa-AgCP59-4B7-AgCP39
plasmid supplied the AgCP regulatory sequences, as well as a
partial E tag sequence, for both the pBacEGFP AgCP59-m1C3-
AgCP39 and the pBacEGFP AgCP59-m4B7-AgCP39 plasmids.
The pSLfa-AgCP59-4B7-AgCP39 plasmid was cloned in several
steps. First, the Mouse ScFv Module/Recombinant Phage
Antibody System (Amersham Biosciences) was used to produce a
single chain antibody from VH and VL cDNA from the 4B7 cell
line. The scFv was cloned into the pCANTAB 5E vector in frame
with the E-Tag at the C terminus. BclI sites were added to both
ends of 4B7 scFv by amplification using primers 4B7BclF [59-
CGTGATCAGTGAAGCTGGTGGAGTCT-39] and 4B7BclR
[59-CGTGATCACTATGCGGCACGCGGTT-39] from the 59
and 39 end and cloning into pCR4Blunt-TOPO. The pGEM-
T[AgCP-SM1] plasmid, containing AgCP (AGAP009593) regula-
tory regions, was generously provided by Dr. Marcelo Jacobs-
Lorena [22]. The BclI-cut 4B7 scFv fragment from TOPO
[4B7BclI] was sub-cloned into the Bam HI sites of pGEMT[AgCP-
SM1] thereby swapping the SM1 fragment with 4B7. AgCP59-
4B7-AgCP39 was cloned subsequently into pSLfa1180fa [40] using
enzymes SacII and SalI. ApaI and SgrAI were used to replace the
4B7 region of pSLFA-AgCP59-4B7-AgCP39 with the commercial-
ly-synthesized m4B7 gene. AgCP59-m4B7-AgCP39 sequence was
then joined to pBacEGFP [40] using a 59 blunt ligation of AscI and
KpnI sites, and a 39 FseI ligation. To assemble the m1C3
transformation plasmid, the enzymes ApaI and BamHI were used
to replace the 4B7 region of pSLfa-AgCP59-4B7-AgCP39.
AgCP59-m1C3-AgCP39 was then joined to pBacEGFP using AscI
restriction sites.
Microinjection and southern hybridization analyses
Microinjection of the pBac [3xP3-EGFP]-m1C3, pBac [3xP3-
EGFP]-m4B7 or pBac [3xP3-dsRed]-m2A10 plasmids with the
piggyBac helper plasmid was performed as described previously,
except that 0.1 mM p- nitrophenyl p9-guanidinobenzoate was
omitted from isotonic buffer [41]. Each G0 male was mated with
15 virgin females and groups of 5–10 G0 females were mated with
5 males, and G1 progeny were screened as larvae with UV-
fluorescence microscopy for the presence of the marker genes.
Standard Southern blotting and hybridization techniques were
used to detect transgene integration [42]. Genomic DNA was
extracted from groups of six transgenic or wild-type control
females as described previously, except that DNA pellets were re-
suspended in 100 mlo fd H 2O [43]. The probe used to identify
m1C3 integration was amplified from a plasmid thought to
contain the EGFP ORF, but which in fact contained the ECFP
ORF. These two ORFs share 99% nucleotide sequence identity,
so it is likely that the ability of the probe to hybridize to the
integrated gene was affected negligibly. The EGFP probe was
generated from pMos[3xP3-EGFP] [37] using XbaI and SacI
enzymes. The m4B7 probe was generated through a restriction
Table 2. Oocyst and sporozoite prevalence and mean intensity of infection in P. falciparum-infected mosquitoes.
Exp. Strain
Oocyst
prevalence
a (n)
Mean intensity of oocyst
infection
a +/2 SD (n)
sporozoite
prevalence (n)
Mean intensity of sporozoite
infection +/2 SD (n) P
b
1 Control 83% (12) 8.4+/28.1 (10) 89% (9) 5887+/25627 (8) 0.0441
m2A10 82% (11) 5.1+/24.4 (9) 50% (8) 2810+/22823 (4)
2 Control 92% (12) 12.9+/210.7 (11) 81% (21) 10979+/215002 (17) 0.0525
m2A10 92% (12) 10.6+/28.5 (11) 71% (21) 3521+/24270 (15)
3 Control 100% (10) 31.2+/218.4 (10) 100% (10) 57116+/262539 (10) 0.0446
m2A10 90% (10) 34.9+/229.2 (9) 90% (10) 19173+/227834 (9)
4 Control 90% (10) 30+/219.8 (9) 100% (23) 58199+/257645 (23) ,0.0001
m2A10 100% (11) 29.5+/216.4 (11) 74% (23) 9434+/217141 (17)
5 Control 70% (10) 14.6+/213.9 (7) 98% (49) 19529+/249509 (48) ,0.0001
m2A10 70% (10) 15.0+/212.5 (7) 67% (49) 528+/21123 (33)
6 Control 90% (10) 10.2+/28.0 (9) 98% (50) 17383+/265246 (49) ,0.0001
m2A10 90% (10) 8.4+/26.1 (9) 44% (50) 622+/21678 (22)
7 Control 82% (11) 4.7+/23.2 (9) 78% (50) 17913+/239420 (39) ,0.0001
m2A10 80% (10) 4.4+/23.3 (8) 14% (50) 450+/21024 (7)
aPrevalence and mean intensity of infection are as described in Table 1.
bA Mann-Whitney U test was used to evaluate statistical significance of sporozoite mean intensity of infection data. A one-tailed P value is listed for each experiment.
doi:10.1371/journal.ppat.1002017.t002
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and FseI. The m2A10 probe was generated through a restriction
digest of the pBSK-m2A10 plasmid with both BamHI and BstBI.
Probes were labeled with
32P using the Megaprime DNA labeling
system (Amersham).
RT-PCR
Total RNA was isolated from whole or dissected mosquitoes
using Trizol (Invitrogen). For m2A10 RT-PCR analyses, 10 males
or 2–3 whole females were used for each RNA preparation. One
microgram of RNA was treated with DNAseI (Promega) for each
50 ml RT-PCR reaction. For m4B7 and m1C3 RT-PCR analyses,
6 males, 4–15 female midguts, or 4 female carcasses were used for
each RNA preparation. Two hundred fifty nanograms of RNA
were treated with DNAseI for each 12.5 ml RT-PCR reaction.
Gene-specific primers and a OneStep RT-PCR Kit (Qiagen) were
used for amplification of diagnostic products from m2A10, m4B7,
m1C3, AsCPA [32], AsVg1 [23], or An. stephensi ribosomal protein
S26 gene [23] transcripts (Table S2). For m2A10 RT-PCR
analyses, amplification of diagnostic products from AsVg1 and
ribosomal protein S26 gene-specific primers was performed in a
single reaction. Diagnostic amplification reactions for the m4B7
25.1 and m1C3 P4.1 lines were initiated with one cycle at 50uC for
30 m, one cycle at 95uC for 15 m, 32 cycles denaturation at 94uC
for 30 s, annealing at a reaction-specific temperature (Table S2)
for 30 s, and extension at 72uC for 1 m, followed by a final
extension at 72uC for 10 m. Diagnostic amplification reactions for
the m2A10 44.1 line were performed as described, except that 30
cycles of amplification were completed. For each sample, an
additional control RT-PCR reaction tested for the presence of
genomic DNA contamination using ribosomal protein S26 gene
primers but omitting the reverse transcription step. Multiple
biological replicates ($2) were performed for selected time points
for each of the RT-PCR series of experiments.
Real-time quantitative RT-PCR analysis
Female mosquito midguts and carcasses and male midguts were
dissected in phosphate-buffered saline (PBS), homogenized in
Trizol Reagent (Invitrogen), and total RNA extracted. Midguts
were dissected at different time points (4 h, 8 h, 16 h, 24 h, 48 h,
72 h, 7 d, and 15 d) after a bloodmeal. RNA was treated with
DNase I (Invitrogen) at 1 U/mg RNA to remove potential genomic
DNA contamination. Further purification was performed using a
DNA-free kit (Ambion). A total of 0.4 mg of RNA was used for
reverse transcription in a reaction volume of 20 ml using
ThermoScript RT-PCR System (Invitrogen). Real-time quantita-
tive PCR was performed on an Opticon 2 Real-Time PCR
Detection System using the Opticon Monitor software version 3.1
(Bio-Rad laboratories). m1C3 expression was quantified with
Platinum SYBR Green qPCR SuperMix UDG with ROX
(Invitrogen) using gene-specific primers (Table S2) to amplify a
diagnostic fragment 211 bp in length. A series of quantitative
standards were generated from serial 10-fold dilutions (a range of
10
10-1 molecules) of TOPO-m1C3scFv, in which full-length
m1C3 was cloned. Each assay was run in triplicate wells in a
25 ml final reaction volume containing 2.5 ml of Platinum SYBR
Green, 400 nM each forward and reverse primer, and 2.5 ml
cDNA sample. Each run included negative controls consisting of
wild-type control cDNA and water instead of cDNA. The
amplification protocol consisted of 2 min at 50uC, 2 min at
95uC, followed by 40 cycles of amplification (94uC for 15 s, 60uC
for 45 s, plate read of SYBR Green I fluorescence), after which a
melting-curve reaction was conducted from 42uCt o9 5 uC with
plate readings every 1uC. GraphPad Prism software was used to
calculate statistical significance using paired T-tests.
Immunoblot analysis
Mosquitoes were blood-fed on chickens and homogenized in a
protease inhibitor solution made from complete mini (Roche) and
Pefabloc SC (Roche). An equal volume of Laemmli sample buffer
(Bio-Rad) with 0.1 M dithiothreitol was added. Homogenates
were separated on a 12% Tris-HCl polyacrylamide gel in 16Tris/
Glycine/SDS buffer (Bio-Rad), transferred to Immun-Blot PVDF
membrane (Bio-Rad), and incubated with goat anti-E tag
polyclonal antibody conjugated to horse radish peroxidase
(Abcam). ECL Plus Western Blotting Detection Reagents (GE
Healthcare) were used to detect bound antibody. Ten females
were used for each hemolymph sample preparation. Legs were
removed with forceps and the proboscis was cut with a scissor.
Individuals were inserted into a pipette tip plugged with glass wool
and threaded through a 0.5 ml tube placed in a 1.5 ml collection
tube. Centrifugation at 530 g for 10 min at 4uC extracted
hemolymph. Each hemolymph sample was mixed with 25 ml
0.15 M NaCl and centrifuged at 2040 g for 5 min at 4uC. Fifteen
microliters of the middle fraction of the sample was transferred to
a new 1.5 ml tube, to which 10 ml of the protease inhibitor
solution was added. For immunoblots with non-denatured
samples, native sample buffer (Bio-Rad), 4–15% Tris-HCl
polyacrylamide gels (Bio-Rad), 16Tris/Glycine electrophoresis
buffer (Bio-Rad), and native transfer buffer (25 mM Tris, 25 mM
Glycine, pH 9.2) were used.
Parasite challenge experiments
Four to six day-old transgenic and wild type female mosquitoes
were fed with P. falciparum NF 54 gametocytes using a membrane
feeding apparatus. After 15 min of feeding, un-engorged mosqui-
toes were removed and engorged mosquitoes were maintained in
the insectary under standard conditions [37] with daily access to a
10% sucrose solution or water and raisins. Midguts were dissected
9 days after the infectious bloodmeal, stained with 0.1%
mercurochrome and the number of oocysts in each preparation
counted. Uninfected bloodmeals were provided to transgenic and
wild-type control mosquitoes following the membrane feeding. For
the m4B7 25.1 experiments, mosquitoes were allowed to feed on
the first and second days post-infection. Mosquitoes in the m2A10
experiments were allowed to feed on the 4
th,8
th, and 12
th days
post-infection. Engorged and un-engorged females were not
separated after the uninfected bloodmeals in m2A10 experiments
1–4, while un-engorged females were discarded in experiments 5–
7. Samples of wild-type control and m2A10 females were dissected
for oocyst counts on the 10
th day post-infection. The salivary
glands of all remaining m2A10 and wild-type control females were
dissected 17–19 days post-infection. A hemacytometer was used in
m2A10 experiments 1–4 to count salivary gland sporozoites [13].
The samples in experiments 5–7 were dried on 6 mm well slides
and stored at 220uC. Sporozoites were stained using SlowFade
Gold antifade reagent with DAPI (Invitrogen) and counted with a
Zeiss Axioskop using the Axiovision camera and software.
Sporozoites were counted using one of three methods, depending
on parasite density. Method 1: If the number of sporozoites in
each of five fields was counted, and a total of 3 or more sporozoites
was found, an average sporozoite/mm
2 measurement was
calculated. When a field contained greater than 50 parasites,
Improvision Volocity software was used to count the number of
sporozoite nuclei in the DAPI image (Measurement protocol: 1.
Find 2D nuclei: separate touching nuclei with a separation guide
of 0.4 mm, reject nuclei with an area of less than 0.2 mm
2.2 .
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2). Method 2: If
the 3 sporozoite requirement of method 1 was not met, fields were
examined until 3 sporozoites were counted, and an average
sporozoite/mm
2 measurement was calculated. Sporozoite/mm
2
values were used to calculate the total number of sporozoites
present in the 6 mm
2 slide well area. Method 3: If a total of 3
sporozoites was not found in up to 25 fields, the entire 6 mm
2 slide
well area was examined for an exact count. GraphPad Prism
software was used to calculate statistical significance using Mann-
Whitney U tests.
Accession numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank/) ac-
cession numbers for the m1C3, m4B7, and m2A10 genes are
HQ315886, HQ315885, and HQ315884, respectively.
Supporting Information
Figure S1 Immunoblot loading controls. Coomassie-stained
polyacrylamide gels used in immunoblot analyses of m2A10
expression. (A) Polyacrylamide gels used in m2A10 immunoblot
presented in Figure 4A. (B) Polyacrylamide gel used in m2A10
immunoblot presented in Figure 4B. (C) A Coomassie-stained
polyacrylamide gel loaded with an equal volume of each sample
used in the immunblot of non-denatured hemolymph samples
(Figure 3C) displayed protein migration. All labeling as in Figure 4.
(TIF)
Table S1 Comparison of Anopheles gambiae (256,340 codons) and
Mus musculus (18,786,705 codons) codon usage for select amino
acids [23].
(DOC)
Table S2 Transgene-specific primers used in expression
analyses.
(DOC)
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